Autophagy is the cell's primary mechanism to degrade damaged organelles and cytoplasm and to protect itself from toxic protein aggregates not degradable by the proteasome. We will address new leads revealing induction and impairment of autophagy in Alzheimer's Disease (AD), identifying its role in Abeta generation, and showing for a requirement for presenilin (PS1) in autophagy function. The hypothesis that autophagy is impaired in AD will be investigated in human brain and FAD fibroblasts, cell lines, and mouse models of AD pathology (Aims 1 and 2). Novel antibodies marking specific compartments of the autophagic pathway and other organelles will be used in double-immunofluorescence and ultrastructural studies (including immunogold), along with other state-of-the-art techniques, to define the nature and significance of autophagy dysfunction in AD. The roles of PS1, PS2, and g-secretase activity in modulating autophagy will be determined and the basis for the observed selective impairment in autophagy-mediated protein degradation caused by FAD-related PS1 mutations will be investigated (Aim 2). We will also investigate the basis for distinctive autophagy abnormalities in Trisomy 21 (Down syndrome) and test the hypothesis that FAD-related APP mutations (Aim 3) also impair autophagy. Autophagy as a neuroprotective mechanism will be studied in primary neurons from normal mice, AD mouse models, and a novel transgenic mouse expressing GFP-tagged LC3, a protein associated with autophagy induction, which will enable real-time visualization of autophagy and will facilitate in vivo studies of autophagy modulation (Aim 4). As a prelude to modulating autophagy as a therapeutic intervention in neurodegenerative disease, we will investigate strategies to manipulate autophagy in the brain in vivo (Aim 4). These ongoing studies, the first to investigate autophagy systematically in AD, will provide a comprehensive assessment of the impact of autophagy and autophagy dysfunction and identify novel approaches to treat proteinopathies, including AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG017617-06
Application #
6920487
Study Section
Special Emphasis Panel (ZAG1-ZIJ-9 (J4))
Project Start
2005-04-01
Project End
2010-03-31
Budget Start
2005-04-01
Budget End
2006-05-31
Support Year
6
Fiscal Year
2005
Total Cost
$340,063
Indirect Cost
Name
Nathan Kline Institute for Psychiatric Research
Department
Type
DUNS #
167204762
City
Orangeburg
State
NY
Country
United States
Zip Code
10962
Nuriel, Tal; Peng, Katherine Y; Ashok, Archana et al. (2017) The Endosomal-Lysosomal Pathway Is Dysregulated by APOE4 Expression in Vivo. Front Neurosci 11:702
Kaur, G; Pawlik, M; Gandy, S E et al. (2017) Lysosomal dysfunction in the brain of a mouse model with intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein. Mol Psychiatry 22:981-989
Yang, Dun-Sheng; Stavrides, Philip; Kumar, Asok et al. (2017) Cyclodextrin has conflicting actions on autophagy flux in vivo in brains of normal and Alzheimer model mice. Hum Mol Genet 26:843-859
Gauthier, Sébastien A; Pérez-González, Rocío; Sharma, Ajay et al. (2017) Enhanced exosome secretion in Down syndrome brain - a protective mechanism to alleviate neuronal endosomal abnormalities. Acta Neuropathol Commun 5:65
Peng, Katherine Y; Mathews, Paul M; Levy, Efrat et al. (2017) Apolipoprotein E4 causes early olfactory network abnormalities and short-term olfactory memory impairments. Neuroscience 343:364-371
Rao, Mala V; Campbell, Jabbar; Palaniappan, Arti et al. (2016) Calpastatin inhibits motor neuron death and increases survival of hSOD1(G93A) mice. J Neurochem 137:253-65
Jiang, Ying; Rigoglioso, Andrew; Peterhoff, Corrinne M et al. (2016) Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF. Neurobiol Aging 39:90-8
Morales-Corraliza, Jose; Wong, Harrison; Mazzella, Matthew J et al. (2016) Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-? Alterations in a Monkey Model of Type 1 Diabetes. J Neurosci 36:4248-58
Colacurcio, Daniel J; Nixon, Ralph A (2016) Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res Rev 32:75-88
Mathews, Paul M; Levy, Efrat (2016) Cystatin C in aging and in Alzheimer's disease. Ageing Res Rev 32:38-50

Showing the most recent 10 out of 148 publications